Cambridge, Massachusetts and Baltimore-based Thrive Earlier Detection Corp, a healthcare company focused on incorporating earlier cancer detection into routine medical care, has named Seema Singh Bhan as senior vice president, public policy and external affairs. She is the former vice president, head of public policy for Foundation Medicine. Thrive Earlier Detection’s backers include Third Rock Ventures, Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group and Exact Sciences.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Thrive Earlier Detection Corp., a company dedicated to extending and saving lives by incorporating earlier cancer detection into routine medical care, today announced the appointment of Seema Singh Bhan as senior vice president, public policy and external affairs, effective September 23, 2019.
“The Thrive team, our board and our founders are all excited to welcome Seema to our organization. Her leadership skills, experience and influence will help pave a path for Thrive supporting our work with policymakers, regulatory agencies, public and private payors, professional organizations and guidelines committees, as well as with patient advocacy groups,” said David J. Daly, chief executive officer. “Seema has a very strong track record of success in creating awareness and generating support for important healthcare related initiatives from the FDA, to CMS, to Capitol Hill, and across the entire landscape. She will have an immediate impact on our ongoing efforts to bring earlier cancer detection into routine medical care, and we are thrilled to have such an accomplished professional joining our team.”
Ms. Singh Bhan brings almost 20 years of experience in policy, government and external affairs. Prior to joining the Thrive team, she served as vice president, head of public policy for Foundation Medicine, where she was responsible for developing, advocating and executing company positions before Congress and the policymakers at the U.S. Food and Drug Administration (FDA), including the landmark parallel review decision by the FDA and Centers for Medicare and Medicaid Services (CMS) on next generation sequencing for Foundation Medicine’s flagship product. Prior to her work in industry, Ms. Singh Bhan served as senior counsel to Senator Arlen Specter, where she was lead policy and strategic advisor for issues related to tax, banking, healthcare and finance. She was also lead counsel to the Senate Judiciary Committee, providing policy analysis and strategic counsel to both Chairman Specter and Republican and Democrat senators on the Committee. Ms. Singh Bhan has extensive experience building consensus amongst a range of policy stakeholders, including elected officials, regulatory agencies, academics, industry groups and individuals.
“This is a profoundly exciting moment in time where we are close to fundamentally bending the arc of cancer care,” said Ms. Singh Bhan. “I am truly humbled and excited to be joining the innovative and patient-centric team at Thrive Earlier Detection.”
About Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. is a healthcare company focused on incorporating earlier cancer detection into routine medical care to extend and save lives. Thrive is developing CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of disease that will serve as the core of its integrated cancer information offering.
CancerSEEK is designed to be administered to healthy adults during routine medical care, such as a yearly checkup, alongside existing cancer screening tools. The company was launched in 2019 by Third Rock Ventures, with funding from additional investors Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group, Exact Sciences and others. For more information, please visit www.thrivedetect.com.